Search ORMP
Oramed Pharmaceuticals Inc.
NasdaqCM · CIK 1176309
Last close4.49
Daily change+0.01 (0.22%)
10 Years gain-34.80%
Dividends TTM0.25
Dividend yield5.58%
Fundamental Analysis
ORMP · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
34.8Momentum
100.0Acceleration
100.0Confidence
88.0Annual Revenue9
Quarterly Revenue33
Annual CFO15
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth0.0 / 25
Quality11.4 / 25
Capital Efficiency6.8 / 20
Balance Sheet11.4 / 15
Shareholder Economics3.5 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 374.1013 percentage points.
ROIC expansionROIC improved by 10.819 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Negative FCF · HIGHLatest free cash flow is negative.
High SBC · MEDIUMStock based compensation is high relative to revenue or FCF.
Key Metrics
Revenue Growth TTM-31.62%OK
Revenue CAGR 3Y-9.55%OK
Gross Marginn/aMISSING
Operating Margin-687.95%OK
FCF Margin-460.4%OK
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-7.74%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFO1.91xOK
Diluted Share Growth 1Y5.93%OK
SBC / Revenue260.4%OK
SBC / FCF-56.56%OK
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $2.00M | $13,000.00 | -$15.09M | -$9.15M | -$9.15M | 0.65% | -754.4% | -457.7% | -10.83% | 42.42M |
| 2025 FY Dec 31, 2024 | n/a | n/a | -$12.78M | -$8.41M | -$8.43M | n/a | n/a | n/a | -8.54% | 40.85M |
| 2024 FY Dec 31, 2023 | $1.34M | n/a | -$15.77M | -$10.30M | -$10.55M | n/a | -1,176.79% | -787.24% | -9.74% | 40.57M |
| 2023 FY Dec 31, 2022 | $2.70M | n/a | -$40.60M | -$27.92M | -$28.41M | n/a | -1,501.96% | -1,051.2% | -29.48% | 39M |
| 2022 FY Aug 31, 2021 | n/a | n/a | n/a | -$21.18M | -$21.56M | n/a | n/a | n/a | n/a | n/a |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $2.00M | sum latest 4 fiscal quarters Revenue | OK | 0001213900-24-095397, 0001213900-24-068992 |
| Revenue Growth TTM | -31.62% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001213900-24-095397, 0001213900-24-068992 |
| Revenue CAGR 3Y | -9.55% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001213900-26-034835 |
| Revenue CAGR 5Y | -5.85% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001213900-26-034835 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001213900-26-034835 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001213900-24-095397, 0001013762-25-003450 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | 0001213900-24-095397, 0001213900-24-068992 |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Margin | -687.95% | Operating Income / Revenue | OK | 0001213900-24-095397, 0001213900-24-068992 |
| FCF Margin | -460.4% | (CFO - CapEx) / Revenue | OK | 0001213900-24-095397, 0001213900-24-068992 |
| CFO / Net Income | -0.6x | CFO / Net Income | OK | 0001213900-24-095397, 0001213900-24-068992 |
| FCF / Net Income | -0.6x | FCF / Net Income | OK | 0001213900-24-095397, 0001213900-24-068992 |
| ROIC | -7.74% | NOPAT / Average Invested Capital | OK | 0001213900-24-095397, 0001013762-25-003450 |
| Net Debt / CFO | 1.91x | Net Debt / CFO | OK | 0001213900-25-076668, 0001213900-24-095397 |
| Current Ratio | 26.81x | Current Assets / Current Liabilities | OK | derived |